mobile
news-insights-top

News & Insight

At Palisade Capital Management, we think differently than other asset managers. We believe in sharing ideas and research across teams—and now with you. Here you can gain access to our vast intellectual capital and decidedly different perspective, while seeing what we’ve been up to lately.



Wednesday, September 24, 2014
PCEPII Portfolio Company Brickell Biotech Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis and Welcomes Charlie Stiefel and Bill Ju to Board of Directors
Posted in Private Equity News
Brickell Biotech, Inc. (“Brickell”), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative therapeutics to satisfy current unmet human needs in the global dermatology markets, today announced the outcome of a pilot study of a new compound, BBI-4000, for the topical treatment of primary axillary hyperhidrosis, or excessive sweating.
Sunday, July 20, 2014
PCEPII Portfolio Company Shoe Sensation Opening its 100th Store and Celebrating 30th Anniversary
Posted in Private Equity News
Shoe Sensation is taking rural communities by storm as it opens its 100th store this year and celebrates 30 years of bringing well-known footwear brands to small-town America. "We have been able to survive through the thick and thin of the economy and expand our model currently to 14 states – 16 states come September," CEO Mike Zawoysky says. “We have been able to deliver new stores each year and comparable store growth for each of the past six consecutive years."
Tuesday, July 01, 2014
Telerx Completes Acquisition of PPP Portfolio Company C3i to Enhance Pharmaceutical Solutions, Services and Global Capabilities
Posted in Private Equity News
Telerx, a leader in U.S. customer care services, today announced that it has completed its acquisition of C3i, a leading provider of technology support services for the life sciences industry. This acquisition will provide Telerx with the global infrastructure to expand its business services outside the United States while maintaining its current domestic operations. The acquisition was completed on June 30, 2014.
Monday, June 30, 2014
PCEPII Portfolio Company Brickell Biotech Announces Licensing Agreement for its Novel Retinoid Therapy with Merz North America
Posted in Private Equity News
Brickell Biotech, Inc. ("Brickell"), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative, therapeutics to satisfy current unmet human needs in the global dermatology markets, today announced that it has entered into a license agreement with Merz North America, Inc. ("Merz"). The agreement grants Merz an exclusive North American license, with certain additional international rights, to develop and commercialize a completely novel retinoid compound, BBI-3000, for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis.
Tuesday, May 20, 2014
Palisade Capital Management CIO - Institutional Dennison T. Veru Appears on Fox Business “Opening Bell with Maria Bartiromo”
Posted in Media Appearances
On May 20, 2014, Palisade Capital's Chief Investment Officer - Institutional Dennison T. Veru appeared on Fox Business with Maria Bartiromo”.
Read More
Monday, April 28, 2014
PPPII Portfolio Company Promosome and GE Healthcare Life Sciences Sign Licensing Agreement
Posted in Private Equity News
GE Healthcare Life Sciences (NYSE: GE) and Promosome LLC announced today that the companies have signed a licensing agreement, granting GE Healthcare exclusive rights to an innovative suite of mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture. Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.
‹ First  < 26 27 28 29 30 >  Last ›
Latest Research and White Papers
Monday, November 21, 2022
Short Duration Convertible Bonds: A Compelling Alternative to Traditional Fixed Income
The U.S. Federal Reserve’s fight against inflation through increases in the Fed Funds rate and quantitative tightening has led to the worst year on record for the U.S. fixed income markets (as measured by Bloomberg U.S. Aggregate Bond Index performance of -15.7% year-to-date through October 31, 2022). This environment, when combined with the potential for additional rate hikes, has resulted in significant losses to fixed income portfolios.
Find Out More and Request This White Paper

See all Research and White Papers



Select A Category

Connect with Us

One Bridge Plaza, Suite 1095, Fort Lee, New Jersey 07024 | (201) 585-7733 | Get Directions | Contact Us

Stay Informed

Sign up for our mailing list and stay up to date on the latest information and news from Palisade Capital Management.